N-Phenylacetyl-L-Prolylglycine Ethyl Ester (Noopept): A Biochemical Analysis of AMPAR Modulation, BDNF Upregulation, and Cholinergic Depletion Risk

Author: RoadToPosterboy

Date: August 2026

Category: Nootropics, Neurochemistry & Cognitive Enhancement

TL;DR / Quick Summary

- Not "Just Stronger Piracetam": Noopept is a low-dose prodrug that uses PEPT1/PEPT2 transporters to cross the BBB. In the brain, it cleaves into cPG (cyclo-L-prolylglycine), driving long-term BDNF & NGF elevation and neuroplasticity.
- The Inverted U-Shape (Dose Warning): More is not better. The sweet spot is 5–10 mg. Taking $> 10 - 15$ mg(especially sublingual) over-saturates AMPA/NMDA receptors with calcium, causing instant brain fog and memory blurs.
- The Choline Rule: Noopept speeds up acetylcholine turnover, causing frontal headaches if stores run dry. Pair it with CNS-bioavailable donors like Alpha-GPC (300 mg) or CDP-Choline (300 mg). *(Note: Choline fixes headaches, but it will NOT fix high-dose glutamate brain fog!)*
- Evidence Base: Backed by solid animal memory tasks (passive/active avoidance) and clinical trials in impaired cohorts (MCI/TBI recovery vs. Piracetam). However, data on healthy humans remains largely theoretical.
- Test Protocol: Testing 10 mg Noopept + 300 mg Alpha-GPC + 300 mg CDP-Choline to hit the optimal dose window while supporting acute ACh pools and long-term membrane repair.

1. Introduction & Pharmacological Profile

Within the field of cognitive neuroenhancement, peptide-derived nootropics occupy a distinct pharmacological position between traditional psychostimulants and classical racetam compounds. N-phenylacetyl-L-prolylglycine ethyl ester (Noopept / GVS-111) was developed as a synthetic dipeptide derivative of piracetam, designed to achieve substantially greater potency in experimental models while maintaining a comparatively favorable safety profile observed in preclinical research.

Unlike central nervous system stimulants such as amphetamines or methylphenidate, which primarily exert their effects through extensive modulation of monoaminergic systems (particularly dopamine and norepinephrine release), Noopept is proposed to influence cognition through a combination of glutamatergic, cholinergic, and neurotrophic mechanisms.

Current pharmacological research suggests that the cognitive effects associated with Noopept may involve several interconnected pathways:

1. Modulation of glutamatergic signaling:
   Noopept and its proposed active metabolite cyclo-L-prolylglycine (cPG) have been associated with alterations in ionotropic glutamate receptor pathways, particularly involving AMPA and NMDA receptor-mediated signaling, which play central roles in learning, memory formation, and synaptic plasticity.
2. Regulation of cholinergic neurotransmission:
   Experimental findings suggest that Noopept may influence cholinergic activity, including mechanisms associated with high-affinity choline uptake (HACU), thereby affecting acetylcholine availability during neuronal signaling.
3. Neurotrophic factor regulation and synaptic plasticity:
   Preclinical studies indicate that Noopept-related pathways may influence the expression of neurotrophic factors such as Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF), which are essential mediators of neuronal adaptation, synaptic remodeling, and long-term potentiation (LTP).

Together, these mechanisms provide a biological framework for understanding how Noopept may influence cognitive processes. Rather than acting as an acute stimulant, its proposed effects are associated with modulation of neuronal signaling pathways involved in synaptic efficiency, plasticity, and memory consolidation.

2. Molecular Mechanisms: How the cPG Pathway May Mediate Noopept's Cognitive Effects

A central topic in the pharmacological evaluation of N-phenylacetyl-L-prolylglycine ethyl ester (Noopept / GVS-111) is determining whether its cognitive effects are mediated primarily by the parent compound or by its active metabolite cyclo-L-prolylglycine (cPG). Pharmacokinetic profiling indicates that parent GVS-111 exhibits a short systemic half-life in rodent models—approximately 5 to 16 minutes—and rapidly declines in central nervous tissues following systemic administration (Boiko et al., 2000, doi:10.1007/BF02439270).

2.1 Enzymatic Biotransformation and Metabolic Profiling

In vivo chromatographic and mass-spectrometric analyses—specifically High-Performance Liquid Chromatography (HPLC) and Gas Chromatography–Mass Spectrometry (GC–MS)—by Gudasheva et al. (1997) demonstrated that within one hour post-administration (5 mg/kg intraperitoneally in rat models), intact GVS-111 was below detectable limits in cerebral tissue. Enzymatic cleavage by plasma and cerebral peptidases yielded three main metabolic products:

1. **Phenylacetic acid**
2. **Prolylglycine**
3. **Cyclo-L-prolylglycine (cPG)**

Among these, only **cyclo-L-prolylglycine (cPG)** exhibited a statistically significant accumulation, showing an approximate **2.5-fold concentration increase** in cerebral tissues relative to baseline controls (Gudasheva et al., 1997, doi:10.1007/BF03189814). These findings support the hypothesis that Noopept functions primarily as a prodrug that elevates central concentrations of cPG—an endogenous cyclic dipeptide.



2.2 AMPAR Interactions and Neurotrophic Factor Expression

Following biotransformation, elevated cPG concentrations are hypothesized to initiate secondary intracellular signaling cascades:

1. **Proposed AMPAR Modulation:** Experimental studies suggest that cPG may function as a positive allosteric modulator of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, potentially delaying receptor desensitization during glutamatergic signaling.
2. **Calcium Influx:** Prolonged channel activity appears to increase intracellular calcium (Ca^{2+}) entry in postsynaptic neurons.
3. **Genomic Response (mRNA Induction):** Increased intracellular calcium is thought to trigger downstream signaling enzymes, resulting in elevated transcription of messenger RNA (**mRNA**) encoding neurotrophic factors.
4. **Neurotrophin Expression in Animal Models:** Experimental data in rodent models indicate a subsequent increase in the expression of two key neurotrophic proteins:
    - **BDNF** (*Brain-Derived Neurotrophic Factor*)
    - **NGF** (*Nerve Growth Factor*)

This signaling cascade is considered a probable biological pathway that supports **Long-Term Potentiation (LTP)**—the persistent strengthening of synapses—and structural dendritic plasticity in hippocampal networks. This mechanism provides a

coherent biological explanation for the observed cognitive-enhancing properties of Noopept in preclinical models.

[Proposed cPG-AMPAR Interaction] —► [Ca^{2+} Influx] —► [mRNA Upregulation] —► [BDNF & NGF Expression] —► [May Contribute to LTP]

2.3 Experimental Observations on Anxiolytic Modulation and TrkB Activation

In addition to parameters associated with memory consolidation, several preclinical animal studies report **anxiolytic-like (anti-anxiety) effects** following GVS-111 or cPG administration without inducing classic sedation. Recent rodent models explore the underlying pathways:

- **Excitatory/Inhibitory (E/I) Balance:** Acute stress and excitotoxic stress disrupt cognitive processing. Experimental data suggest that cPG may influence specific AMPA receptor subunits and interact with inhibitory **GABAergic** (γ-aminobutyric acid) pathways, which may contribute to restoring the Excitatory/Inhibitory (E/I) balance in hippocampal structures (Gudasheva et al., 2020, doi:10.1134/S1607672920040067).
- **TrkB Receptor Pathways:** Furthermore, observations indicate that cPG exposure has been associated with increased TrkB signaling—the primary functional receptor for BDNF (Gudasheva et al., 2022, doi:10.1134/S1607672922060047). Upregulation of TrkB during stress events is hypothesized to mitigate stress-induced synaptic deficits.





Hypothesized AMPAR/GABA Cross-Talk (May Help Restore E/I Balance)

TrkB Pathway Engagement (Associated with BDNF Plasticity)

2.4 Cholinergic Activity and Community-Reported Dynamics

Glutamatergic modulation and increased neuronal activity have been proposed to influence mechanisms associated with High-Affinity Choline Uptake (HACU) and acetylcholine (ACh) metabolism.

In user experience reports, a frequently reported adverse effect in online nootropic communities is the onset of **frontal tension headaches and transient cognitive fatigue**. It has been hypothesized within non-clinical literature that accelerated ACh turnover might exceed endogenous choline availability under specific conditions.

Consequently, the co-administration of exogenous choline donors—such as **L-alpha-glycerylphosphorylcholine (Alpha-GPC)** or **Citicoline (CDP-Choline)**—is a widespread practice in anecdotal nootropic protocols to prevent suspected neurotransmitter exhaustion. However, controlled clinical trial data validating the routine necessity or therapeutic efficacy of this combined protocol remain limited, and further empirical research is required to establish controlled dosage frameworks.

2.5 Methodological Context

Although the majority of mechanistic evidence originates from preclinical models, the convergence of findings involving cPG accumulation, neurotrophic signaling, and synaptic plasticity provides a plausible neurobiological basis for Noopept's reported cognitive effects. Direct human mechanistic confirmation remains an important area for future clinical research.

3. Pharmacokinetics, Administration Routes & Dosing Dynamics

While the molecular mechanisms described above explain *why* Noopept may enhance cognitive function, its pharmacokinetic profile helps explain *how* these effects are achieved despite the compound's short systemic presence. Unlike traditional stimulants that rely on immediate neurotransmitter release, Noopept appears to exert its effects through rapid conversion into biologically active metabolites, particularly cyclo-L-prolylglycine (cPG), which may sustain downstream signaling pathways involved in neuronal plasticity.

A defining feature of Noopept is the efficient metabolic transformation of the parent compound into active central metabolites. This prodrug-like behavior allows the compound to act as a delivery system for cPG, enabling modulation of glutamatergic signaling, neurotrophic pathways, and synaptic adaptation.

The pharmacological impact of Noopept is therefore not determined solely by the concentration of the original molecule, but by the ability to generate and maintain biologically relevant levels of active metabolites within neural tissue. Factors including absorption, enzymatic conversion, and central nervous system distribution contribute to the variability of individual responses and help explain why administration dynamics are a critical component of its cognitive effects.

3.1 Absorption, Bioavailability & Route-Dependent Pharmacokinetics

The pharmacokinetic evaluation of N-phenylacetyl-L-prolylglycine ethyl ester (Noopept / GVS-111) is significantly defined by its route of administration, which governs systemic exposure, peak concentration profiles, and the extent of pre-systemic degradation.

Oral Administration & Intestinal Cleavage

Upon oral ingestion, GVS-111 undergoes rapid gastrointestinal absorption. However, its absolute systemic bioavailability as the intact parent compound remains low (estimated at $< 10\%$in rodent models). This limitation is primarily attributed to extensive enzymatic hydrolysis:

- **Peptidase Cleavage:** Gastrointestinal and hepatic peptidases rapidly cleave the dipeptide ester backbone, producing phenylacetic acid, prolylglycine, and the endogenous cyclic peptide cyclo-L-prolylglycine (cPG).

- **Pharmacokinetic Profile:** Experimental studies in rat models demonstrate a short time-to-peak plasma concentration ($T_{\text{max}} \approx 7$ minutes / 0.116 hours) following oral administration, followed by a rapid systemic decline (Boiko et al., 2001, PMID: 11177261).
- **Prodrug Efficacy:** Despite low parent-compound bioavailability in systemic circulation, oral administration retains pronounced neurochemical activity. This confirms that Noopept acts predominantly as a central prodrug, facilitating sustained biological effects via the downstream accumulation of its active metabolite, cPG, within hippocampal networks.

Sublingual and Parenteral Pathways

To bypass the extensive enzymatic degradation associated with the gastrointestinal tract, non-oral administration routes—specifically sublingual and intranasal delivery—are widely discussed in non-clinical and exploratory literature:

- **Hepatic Portal Bypass:** Sublingual administration allows direct absorption through the oral mucosa into the systemic venous circulation, bypassing hepatic first-pass metabolism and intestinal peptidase degradation.
- **Pharmacodynamic Implications:** By avoiding pre-systemic breakdown, sublingual delivery yields a substantially higher peak concentration (C_{max}) per milligram of administered substance compared to oral ingestion. Consequently, lower nominal doses (e.g., 5--10 mgsublingually versus 10--20 mgorally) achieve equivalent or superior central receptor engagement.

[Administration Route]



3.2 Crossing the Blood-Brain Barrier & The cPG Transformation

A common misconception in the community is that Noopept is just "super-concentrated Piracetam." Looking at the biochemistry reveals a much cooler reality: Noopept is essentially a high-tech delivery vehicle for an endogenous neuropeptide.

Standard dipeptides (short protein chains) are hydrophilic (water-soluble) and struggle massively to cross the Blood-Brain Barrier (BBB). To solve this, researchers at the Zakusov Institute (Gudasheva et al.) engineered a smart two-pronged solution:

1. The "Lipid Shield" (Passive Diffusion)

- Structural Addition: Noopept features an aromatic phenylacetyl group attached to its N-terminus.
- Mechanism: This lipophilic moiety drastically boosts the molecule's octanol-water partition coefficient ($\log P$).
- Result: It allows Noopept to slide directly through the endothelial cell membranes of the BBB via passive transcellular diffusion.

2. Active Carrier-Mediated Influx (PEPT1 & PEPT2)

- Transporter Hijacking: Noopept doesn't just rely on passive diffusion. It acts as a substrate for PEPT1 and PEPT2 (proton-coupled oligopeptide transporters) located on brain capillary endothelial cells.
- Result: The brain actively pumps Noopept across the barrier into central tissue (Gudasheva et al., 2018, DOI: 10.2174/1381612824666181008105641).

The Intracerebral Transformation: How cPG is Born

Once Noopept lands inside the brain parenchyma, a key metabolic sequence takes place:

[Noopept in Brain Parenchyma]

|

▼ Enzymatic cleavage of the lipophilic Phenylacetyl group

[Uncapped Dipeptide]

|

▼ Spontaneous Intramolecular Cyclization (Folds into a ring)

[cyclo-L-Prolylglycin (cPG)] <— Endogenous Neuroplasticity Modulator

|

└► Accumulates in Hippocampal & Cortical Networks

(Drives long-term BDNF & NGF expression)

1. Cleavage: Enzymatic activity strips away the phenylacetyl group.
2. Cyclization: The remaining Proline-Glycine backbone undergoes a spontaneous nucleophilic attack, folding into a cyclic ring structure: cyclo-L-prolylglycine (cPG).
3. Central Tissue Retention: While intact Noopept in the bloodstream has a very brief half-life ($t_{1/2} \approx 7$--15 mins), cPG accumulates and persists inside the hippocampus and cortex.
4. Neurotrophin Surge: This central cPG pool is what sustains long-term AMPA receptor modulation and drives the up-regulation of BDNF (Brain-Derived Neurotrophic Factor) and NGF (Nerve Growth Factor) (Gudasheva et al., 2018, DOI: 10.18097/PBMC20186405455).

Key Takeaway for the Thread: Noopept isn't just the active agent itself—it's a targeted delivery vehicle engineered to flood central brain tissue with the endogenous, neuroplasticity-enhancing cyclic dipeptide cPG.

4. The Choline System & Receptor Dynamics: Why Your Stack Matters

A classic piece of advice on nootropics forums is: *"Always pair Noopept with a choline donor."* While there is sound neurochemistry behind this, most people completely confuse **which** choline source to use and **what** choline actually fixes.

4.1 Acetylcholine Turnover vs. Glutamate & Apoptotic Protection

To optimize your protocol, you have to separate three distinct neurochemical pathways:

1. **Acetylcholine (**ACh**) Depletion:** Noopept accelerates AChturnover in the hippocampus. When presynaptic stores deplete, you get the infamous "nootropic frontal headache."
2. **Glutamate Excitotoxicity:** Excessive doses (e.g., 20 mgsublingually) over-saturate AMPAR/NMDAR complexes. The resulting intracellular calcium (Ca^{2+}) surge leads to receptor desensitization and heavy brain fog. **Choline supplements cannot undo glutamate overstimulation.**
3. **Downstream Neuroprotective Cascade:** Beyond neurotransmitters, Noopept actively shields neurons. A landmark study (*Ostrovskaya et al., 2014; DOI: 10.1186/s12929-014-0074-2*) proved that Noopept attenuates cellular apoptosis, restores mitochondrial function, and reduces **Tau hyperphosphorylation**.

[Noopept (Balanced Dosing)] —► Sustained ACh Turnover

—► Needs Bioavailable Choline

|

├—► Rescues Mitochondria & Lowers Tau (Ostrovskaya et al., 2014)

|

└—► Avoids AMPAR Desensitization & Brain Fog

4.2 Comparing Choline Donors: Alpha-GPC vs. CDP-Choline vs. Bitartrate

Not all choline supplements work. The defining factor is **Central Nervous System (CNS) Bioavailability**.

[Choline Bitartrate] —► Hydrophilic Salt —► Blocked at BBB

—► Peripheral Only (Useless for Noopept)

[Alpha-GPC] —► Phospholipid —► Crosses BBB

—► Rapid ACh Pool Replenishment

[CDP-Choline] —► Cytidine Hybrid —► Crosses BBB

—► ACh Replenishment + Membrane Repair

1. Choline Bitartrate (The Trap)

- **Mechanism:** Simple ionic salt. Highly hydrophilic.
- **BBB Penetration:** Very poor. It relies on saturated peripheral transporters and barely crosses into central tissue.
- **Verdict: Useless for Noopept.** It targets liver fat metabolism, leaving brain AChpools starving.

2. Alpha-GPC (L-Alpha-Glycerylphosphorylcholine) — ~300 mg Standard

- **Mechanism:** Lipophilic phospholipid structure that easily crosses the BBB.
- **Pharmacodynamics:** Rapidly cleaves into free choline inside the CNS, acting as an immediate substrate for choline acetyltransferase (ChAT).
- **Best Used For:** Fast, acute protection against presynaptic AChdepletion during intense cognitive work.

3. CDP-Choline (Citicoline) — ~300 mg Standard

- **Mechanism:** Dual-action prodrug breaking down into choline and cytidine (which converts to uridine in the brain).
- **Pharmacodynamics:** Replenishes AChwhile simultaneously feeding the *Kennedy Pathway* to synthesize phosphatidylcholine for neuronal membranes.
- **Best Used For:** Long-term stacks targeting structural neuroplasticity, working in tandem with Noopept's BDNF/NGF elevation.

Summary Table for Stacking

Parameter	Choline Bitartrate	Alpha-GPC (300 mg)	CDP-Choline / Citicolin (300 mg)
BBB Permeability	Negligible	High	High
Primary Target	Liver & Peripheral tissue	CNS / Hippocampal ACh Pools	ZNS ACh Pools + Membrane Repair
Synergy with Noopept	✗ None	10/10 (Acute ACh Support)	10/10 (Long-term Plasticity)

5. Dose-Response Dynamics & Protocol Design: The Inverted U-Shape

When it comes to Noopept, the biggest mistake people make is assuming that *"if 10 mg is good, 20 mg or 30 mg sublingual must be twice as good."*

In pharmacology, Noopept follows a classic **Inverted U-Shape Dose-Response Curve (Bell-Shaped Curve)**.

- **Under-dosing (<5 mg):** Sub-threshold engagement of AMPA receptors; minimal neurotrophin induction.
- **Optimal Window (5–10 mg):** Modulates AMPA receptors perfectly. Intracellular calcium (Ca^{2+}) influx triggers long-term potentiation (LTP) and up-regulates BDNF/NGF without overwhelming the post-synaptic density.
- **Over-dosing (>15–20 mg sublingually):** Excitotoxic overshoot. Intracellular calcium floods the cell, forcing the brain to internalize and desensitize AMPA/NMDA receptors to protect itself. **Result:** Severe brain fog, short-term memory blurs, and emotional flattening.

5.1 My Personal Self-Experimentation Protocol

To test these biochemical principles in practice rather than relying purely on forum anecdotes, I am running a controlled self-experiment with a calibrated dose and stack:

My Personal Test Protocol:

- **Noopept: 10 mg** (aiming right for that sweet spot on the inverted U-shape curve without triggering receptor desensitization).
- **Alpha-GPC: 300 mg** (to supply immediate, ZNS-bioavailable choline for rapid hippocampal ACh synthesis).
- **CDP-Choline (Citicoline): 300 mg** (to support long-term membrane repair via the *Kennedy Pathway* and synergize with BDNF-driven neuroplasticity).

By capping Noopept at **10 mg** and combining it with **300 mg of both Alpha-GPC and CDP-Choline**, the goal is to hit the absolute sweet spot: providing enough choline to prevent headaches while protecting against the glutamate overload that causes brain fog.

(Disclaimer: This is my personal biohacking self-experiment based on the literature reviewed above. It is not medical advice!)

6. Evidence Beyond Molecular Mechanisms & Critical Appraisal

While understanding the receptor pathways is crucial, a nootropic is only as good as its functional outcomes. To evaluate Noopept fairly, we have to look past the isolated cell dishes and examine the **chain of evidence**—connecting molecular triggers to real behavioral changes, clinical data, and safety limits.

6.1 The Molecular-to-Behavioral Chain of Evidence

The proposed mechanism of action for Noopept does not exist in a vacuum; it forms a logical, multi-tiered cascade:

$$\text{Noopept} \longrightarrow \text{cPG Transformation} \longrightarrow \text{AMPA/NMDA Modulation} \longrightarrow Ca^{2+}\ \text{Signaling} \longrightarrow \text{BDNF/NGF Elevation} \longrightarrow \text{Synaptic Plasticity} \longrightarrow \text{Enhanced Memory Retention}$$

Behavioral Evidence in Animal Models

Preclinical studies consistently bridge this gap using established behavioral protocols:

- **Passive Avoidance Tasks:** Animals treated with Noopept demonstrate significantly increased step-through latencies, indicating improved long-term memory encoding and retrieval.
- **Active Avoidance & One-Session Learning:** Research suggests that Noopept accelerates the acquisition of conditioned reflexes, supporting the hypothesis that it enhances early-phase synaptic consolidation.
- **Cerebral Ischemia & Neurodegeneration Models:** In rodent models of global or focal ischemia, Noopept administration attenuated cognitive deficits, demonstrating accelerated recovery of spatial memory and task performance post-injury.

6.2 Human Clinical Evidence: Is It Just "Stronger Piracetam"?

A common reductionist claim is that Noopept is simply *"1000x stronger Piracetam."* Pharmacology tells a different story.

[Piracetam] ————► Direct Cyclic GABA Derivative

—► Requires High Doses (Grams)

└► Modulates Membrane Fluidity / AMPAR

[Noopept] ————► Prolylglycine Prodrug System

—► Low Milligram Doses (10 mg)

└► Endogenous cPG Cleavage + BDNF/NGF Induction

- **Structural & Mechanistic Divergence:** Piracetam is a classic racetam derivative acting directly as a positive allosteric modulator of AMPA receptors and membrane fluidizer. Noopept is an N-acyl dipeptide ester engineered as a **prodrug for the endogenous neuropeptide cPG**.
- **Human Clinical Findings:** Comparative human clinical trials (primarily in Russia) evaluating mild cognitive impairment (MCI), vascular brain disease, and post-traumatic brain injury indicate that 20 mg/day of Noopept achieved comparable or superior cognitive stabilization to 1200 mg/day of Piracetam—with a noticeably lower incidence of psychostimulatory side effects (such as irritability or fatigue).
- **The "Healthy Human" Caveat:** It is critical to clarify that the vast majority of human data stems from populations with **existing cognitive impairments or vascular deficits**. Robust, large-scale, double-blind randomized controlled trials (RCTs) on healthy, young adult cohorts remain scarce. Extrapolating clinical recovery in TBI patients to "cognitive enhancement" in healthy individuals relies on preclinical hypotheses rather than proven facts.

6.3 Safety Profile & Pharmacological Boundaries

- **Low Toxicity:** Preclinical toxicological screenings indicate a high therapeutic index (LD_{50} is orders of magnitude higher than active effective doses), with low acute and subchronic systemic toxicity.
- **Non-Stimulant Profile:** Unlike amphetamines or methylphenidate, Noopept does not act as a direct monoamine reuptake inhibitor or catecholamine releaser. Its subtle energetic effects stem from neurotrophic and cholinergic modulation rather than central sympathomimetic stimulation.
- **Long-Term Data Limits:** While short-to-medium-term clinical usage (up to 1.5–2 months) is documented in Eastern European pharmacopeia, comprehensive long-term (multi-year) epidemiological safety data in healthy populations is lacking. Continuous, indefinite daily usage without cycling should be approached with caution.

6.4 Final Verdict

Conclusion: Noopept is not a magical pill that "makes healthy humans instantly smarter." However, **multiple independent lines of evidence**—ranging from structural SAR studies and transporter kinetics to BDNF induction, animal avoidance models, and clinical stroke-recovery trials—**support a plausible neurobiological foundation for its cognitive-modulating effects.**

When kept within its tight physiological dose window (5–10 mg) and paired with a CNS-bioavailable choline donor (300 mg Alpha-GPC or CDP-Choline), it stands as one of the most pharmacologically intriguing peptide derivatives available today.

7. References & Selected Bibliography

1. **Boiko, S. S., Zherdev, V. P., Gudasheva, T. A., et al.** (2001). *Pharmacokinetics of GVS-111 and its main metabolite cyclo-L-prolylglycine in rats.* Bulletin of Experimental Biology and Medicine, 131(1), 22–25. [PMID: 11177261]
2. **Gudasheva, T. A., Voronina, T. A., Ostrovskaya, R. U., et al.** (2018). *Design, Synthesis, and Pharmacological Evaluation of Dipeptide Nootropic Agents.* Current Topics in Medicinal Chemistry, 18(24), 2125–2139. [DOI: 10.2174/1381612824666181008105641]
3. **Gudasheva, T. A., Boyko, S. S., Akparov, V. K., et al.** (2018). *Identification and pharmacokinetics of cyclo-L-prolylglycine as a major active metabolite of GVS-111.* Biomedical Chemistry (PBMC), 64(5), 455–461. [DOI: 10.18097/PBMC20186405455]
4. **Ostrovskaya, R. U., Vakhitova, Y. V., Salimgareeva, M. K., et al.** (2014). *Noopept stimulates the expression of NGF and BDNF in rat hippocampus.* Journal of Biomedical Science, 21(1), 74. [DOI: 10.1186/s12929-014-0074-2]
5. **Ostrovskaya, R. U., Gudasheva, T. A., Zaplina, A. P., et al.** (2008). *The nootropic and neuroprotective dipeptide Noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model.* Journal of Psychopharmacology, 22(4), 398–408.